70760 results about "Organic chemistry" patented technology

An organic molecule is disclosed comprising:a first chemical moiety with a structure of formula I,andtwo second chemical moieties, each at each occurrence independently from another consisting of a structure of formula II,wherein the first chemical moiety is linked to each of the two second chemical moieties via a single bond.

The present embodiments provide compounds of Formula I, compositions of the compounds, and methods for treating diseases such as cancer.

The invention provides a polypeptide or a derivative and a pharmaceutically acceptable salt thereof. The amino acid sequence of the polypeptide is as shown in SEQ ID NO: 1. The polypeptide or the derivative and the pharmaceutically acceptable salt thereof disclosed by the invention can be combined with GLP-1R and GCGR, and is used for effectively activating the GLP-1R and the GCGR. Therefore, the polypeptide or the derivative and the pharmaceutically acceptable salt thereof can be used for detecting GLP-1R and / or GCGR, and can also be used for treating or preventing GLP-1R and / or GCGR related diseases (such as metabolic disorder related diseases, such as obesity, diabetes, fatty liver diseases, non-alcoholic fatty liver diseases and the like).

Provided are a pyrimidine polycyclic derivative inhibitor, a preparation method therefor and the use thereof. In particular, provided are a compound as shown in the general formula, a preparation method therefor, a pharmaceutical composition comprising the compound, and the use thereof in the treatment of cancers and other related diseases.

The invention relates to a fused ring compound, a preparation method thereof and application of the fused ring compound in medicine. Specifically, the invention relates to a fused ring compound as shown in a general formula (IN), a preparation method thereof, a pharmaceutical composition containing the compound and application of the fused ring compound as a therapeutic agent, in particular to application of the fused ring compound in preparation of drugs for inhibiting KRAS G12D. Wherein each group in the general formula (IN) is as defined in the specification. # imgabs0 #

The present invention relates to a KRASG12D inhibitor and the use thereof. Specifically, provided in the present invention is a compound as shown in formula (I), and the definition of each substituent in the formula is as described in the description. In addition, the present invention further relates to a composition containing the inhibitor and the use thereof. The compound of the present invention has good tumor growth inhibitory activity, and has good safety.

The present disclosure relates to the use of a metal chelator to treat an exposed photoresist film. In particular embodiments, the metal chelator is employed to remove an interfacial area that is disposed between exposed and unexposed areas or disposed within an exposed area, thereby enhancing patterning quality.

The present invention is directed to a storage-stable formulation of long-chain RNA. In particular, the invention concerns a dry powder composition comprising a long-chain RNA molecule. The present invention is furthermore directed to methods for preparing a dry powder composition comprising a long-chain RNA molecule by spray-freeze drying. The invention further concerns the use of such a dry powder composition comprising a long-chain RNA molecule in the preparation of pharmaceutical compositions and vaccines, to a method of treating or preventing a disorder or a disease, to first and second medical uses of such a dry 10 powder composition comprising a long-chain RNA molecule and to kits, particularly to kits of parts, comprising such a dry powder composition comprising a long-chain RNA molecule.

The invention discloses long-chain alkyl polyarylamine as well as a preparation method and application thereof. The structural formula of the long-chain alkyl polyarylamine is as shown in a formula (I): # imgabs0 # formula (I), wherein R is an alkyl group with the carbon atom number of 5-12, the weight-average molecular weight of the R is 5000-136000 g / mol, and the PDI of the R is 1.41-2.24; the long-chain alkyl polyarylamine provided by the invention has relatively high fluorescence intensity, can stably emit fluorescence at high temperature and under long-term illumination, and has relatively long fluorescence lifetime.

The present disclosure provides compounds and pharmaceutically acceptable salts thereof, and methods of using the same. The compounds and methods have a range of utilities as therapeutics, diagnostics, and research tools. In particular, the subject compositions and methods are useful for reducing signaling output of oncogenic protein.

This invention provides a halogenated compound for 5' end capping of nucleic acids and its applications, the compound being shown in formula (I). This invention also provides the uses and effects of the above-described compound on nucleic acid transcription and expression.

The present disclosure provides compounds according to Formulae I, II, III, IV, V, VI, VII, VIII, IX, X, XI, XII, XIII, XIII, and XIV for use as a component in a lipid nanoparticle composition for the delivery of biological and / or therapeutic agents. The present disclosure also provides novel, stable lipid nanoparticle compositions comprising one or more biological and / or therapeutic agents, as well as methods of making and delivering lipid nanoparticle compositions.

The invention relates to a fused ring compound, a preparation method thereof and application of the fused ring compound in medicine. Specifically, the invention relates to a fused ring compound as shown in a general formula (IN), a preparation method thereof, a pharmaceutical composition containing the compound and application of the fused ring compound as a therapeutic agent, in particular to application of the fused ring compound in preparation of drugs for inhibiting KRAS G12D. Wherein each group in the general formula (IN) is as defined in the specification. # imgabs0 #

The invention discloses polyketide synthase or a polyketide synthase mutant and application thereof, and belongs to the technical field of gene engineering. The polyketide synthase is AspiPKS4, AspiPKS5, AspiPKS6 and AspiPKS7 from cyathea spinulosa, FhPKS2, FhPKS3, FhPKS4, FhPKS5 and FhPKS6 from ficus himalayana, and CrPKS from floating fern. The mutant is obtained by carrying out single point mutation on the second amino acid of AspiPKS7 or deleting an N-terminal redundant sequence. The polyketide synthase or the mutant is used for replacing NnHisspS in an original FBP luminescence system, and the biological self-luminescence level can be remarkably improved. The invention further provides a simplified and improved FBP system which comprises the polyketide synthase or the polyketide synthase mutant, CPH, H3H and Luz, and the application convenience and the application luminescence capacity of the FBP system are improved.

The invention provides a novel acrylonitrile catalyst and a preparation method thereof. The novel acrylonitrile catalyst is prepared from the following raw materials: mixed salt, an active component, silica sol, a rare earth precursor, a carrier and a cosolvent, by introducing the cosolvent and optimizing the carrier structure, the dispersity of the rare earth precursor is improved, the production process is optimized, the doping efficiency of the rare earth precursor is remarkably improved, the activity, selectivity and stability of the novel acrylonitrile catalyst are improved, generation of by-products CO, CO2, acrolein and acrylic acid during acrylonitrile production can be reduced, and industrial efficient preparation is achieved.

The invention relates to a fused heteroaryl compound, a preparation method thereof and application of the fused heteroaryl compound in medicine. Specifically, the invention relates to a fused heteroaryl compound as shown in a general formula (I), a preparation method thereof, a pharmaceutical composition containing the compound and application of the compound as a therapeutic agent, in particular to application of the compound in preparation of drugs for inhibiting KRAS amplification and / or mutant activity. Wherein each group in the general formula (I) is defined in the specification. # imgabs0 #

The invention discloses silk fibroin composite gel and a preparation method thereof, and relates to the technical field of tissue filling materials. The preparation method of the silk fibroin composite gel comprises the following steps: preparing silk fibroin and carrying out amination modification on the silk fibroin to obtain aminated silk fibroin; carrying out dynamic cross-linking on the aminated silk fibroin and the oxidized sodium alginate through a Schiff base bond by adopting an enzyme catalysis cross-linking process to obtain a dynamic cross-linked network solution; adding a temperature-sensitive component into the dynamic cross-linked network solution, and uniformly mixing to obtain a temperature-sensitive-dynamic dual-network pre-gel solution with temperature responsiveness; loading the active component into the temperature-sensitive-dynamic dual-network pregel solution to obtain a composite gel solution; incubating the composite gel solution to obtain primary gel; after disulfide bonds are introduced into the primary gel, cross-linking strengthening and sterilization are carried out, and the silk fibroin composite gel is obtained. Through temperature-sensitive-dynamic dual-network design, active components and disulfide bonds are introduced to strengthen crosslinking, and the problems that traditional injectable gel is irreversible, single in function, prone to collapse after being filled and the like are systematically solved.

The invention belongs to the technical field of genetic engineering, and particularly relates to recombinant collagen based on engineering bacterium expression and a preparation method thereof, and the recombinant collagen is formed by connecting repetitive units derived from human III type collagen in series for three times; the invention also discloses a base sequence of the coding gene of the recombinant collagen, efficient expression and accurate folding of target protein are realized through genetic modification of engineering bacteria, a light-operated dynamic folding process and an orthogonal purification strategy, and cascade purification of a His6-SUMO tag and an intein-CBD module is utilized to obtain the recombinant collagen. The product purity and the native conformation retention rate are remarkably improved, and the technical problems that hydroxyproline depends on exogenous addition, the folding controllability is poor and the purification efficiency is low in a traditional process are solved.

The embodiment of the invention provides a tyrosine ammonia lyase mutant and application thereof in synthesis of p-coumaric acid. The mutant is subjected to any one of the following amino acid mutations on an amino acid sequence as shown in SEQ ID NO. 2: F497I, F497I + L248M, F497I + L248M + M4T, and L248M + F497I + M4T + V482L. According to the embodiment of the invention, an amino acid sequence as shown in SEQ ID NO. 2 is taken as a template, a key active site of the template is subjected to mutation transformation, a mutant library is constructed, and a series of mutants with remarkably improved catalytic activity and / or conversion rate are screened; the tyrosine ammonia lyase mutant provided by the embodiment of the invention can selectively catalyze L-tyrosine to generate p-coumaric acid, and has excellent yield and / or higher yield.

The invention belongs to the technical field of genetic engineering, and particularly relates to an antibacterial peptide with antibacterial and antiviral effects and application and a product thereof. The amino acid sequence of the antibacterial peptide provided by the invention has the following general formula: X1GX2FX3FX4KKFX5LFX6X7SKVLK, x1 is M or has no amino acid; x2 is one of R, G and H; x3 is one of KS, KR, HR and HH; x4 is R or L; x5 is one of KK, HH and HK; x6 is RR or KK; and X7 is I or L. The antibacterial peptide disclosed by the invention has a relatively good antibacterial effect, and shows antiviral activity on HPV16 (Human Papilloma Virus 16) and HPV18 (Human Papilloma Virus 18). Good application prospects are shown in the preparation of antibacterial or antiviral products.

The invention discloses an aerogel fire extinguishing agent for fire fighting, a fire extinguishing device and a releasing method.The aerogel fire extinguishing agent for fire fighting is prepared from, by mass, 8-12 parts of silicon dioxide aerogel powder, 40-45 parts of perfluorohexanone, 1.5-2 parts of zinc molybdate, 0.8-1.2 parts of nano cerium oxide, 2-3 parts of hyperbranched polysiloxane and 0.2-0.3 part of 18-crown-6 ether. Solid-phase silicon dioxide aerogel powder is matched with liquid-phase perfluorohexanone, zinc molybdate, nano cerium oxide, hyperbranched polysiloxane, 18-crown-6 ether and the like are compounded to serve as auxiliaries, efficient fire extinguishing can be conducted on precise electrical elements, residues are few, loss of instruments and equipment is small, and the fire extinguishing agent is suitable for being applied to the electrical field.

Disclosed are a pentapeptide compound and a composition and use thereof, relating to the technical field of polypeptides, the peptide or a salt thereof having a structure as shown in formula (I): R1-Lys-Lys-Leu-Ala-R2 (I). The invention also relates to a cyclic peptide, and the structure of the cyclic peptide is Cyclo-[Lys-Lys-Lys-Leu-Ala]. The compound disclosed by the invention has the effects of controlling oil, repairing, resisting oxidation and the like, and can be used for nursing skin or mucosa.

The invention relates to the technical field of fine chemical engineering preparations, in particular to an environment-friendly non-silicon defoaming agent as well as a preparation method and application thereof. 3.6 to 5.1 parts of a defoaming aid; 0.24 to 0.35 part of a thickening agent; 2-3 parts of a dispersing agent; 2.6 to 3.5 parts of an emulsifier; 18 to 25.3 parts of an organic solvent; 65 to 82 parts of deionized water; wherein the polyether ester A and the polyether ester B with amphiphilic structures in the polyether ester can be quickly spread on the surface of foam, carry hydrophobic components to permeate a liquid membrane and accelerate foam breakage, and the defoaming assistant A and the defoaming assistant B further promote the defoaming and foam inhibition performance of the defoaming agent by reducing competitive adsorption to the defoaming agent and delaying release of active molecules. Compared with the prior art, the method has a wide application prospect.

The invention relates to the technical field of carbon black, in particular to a preparation process of high-adsorbability carbon black, which comprises the following steps: performing pore-forming treatment on carbon black to obtain a porous carbon black material, then treating the porous carbon black material with a first mixed amino acid solution to obtain a carbon black material loaded with a first mixed amino acid adsorption layer, and drying the carbon black material to obtain the high-adsorbability carbon black. And treating the carbon black material with a second mixed amino acid solution to obtain a carbon black material loaded with a second mixed amino acid adsorption layer, and treating the carbon black material loaded with mixed amino acids with laccase and tyrosinase. The carbon black product obtained by the preparation process has high adsorbability, and is used for treating metal ions in wastewater, so that the removal rate of the metal ions is greatly improved.

The invention discloses a preparation method and application of amino-modified single-benzene-ring copper-based MOFs (metal organic frameworks), and the method comprises the following steps: dropwise adding a copper nitrate monohydrate solution into a diamino terephthalic acid solution, fully stirring to react, and centrifugally washing and drying the product to obtain the amino-modified single-benzene-ring copper-based MOFs. The amino-modified single-benzene-ring copper-based MOFs are used for electrocatalytic reduction of carbon dioxide. The prepared amino-modified single-benzene-ring copper-based MOFs have unique morphology, active sites can be exposed on the inner surface and the outer surface, the accessibility of the active sites is improved, and meanwhile the reaction mass transfer capacity is enhanced.

The invention provides methods for the preparation of particles including one or more agents, e.g., therapeutic or diagnostic agents. The particles can be formed by creating droplets of a first liquid, e.g., including an agent, and removing the first liquid, e.g., through its dispersal in a second liquid and / or evaporation, to solidify the droplets. Advantageously, the process of forming the particles does not significantly alter the structure or activity of the agents and may enhance the stability of the agents. For example, the particles may be stored for long periods of time without significant loss of activity, and in some embodiments, without the need for refrigeration. These particles may be used to generate stabilized pharmaceutical compositions for storage or other logistical purposes, pharmaceutical suspensions, pharmaceutical powder formulations (e.g., inhalable powders, injectable powders), creams or other topical pastes, nutraceuticals, or cosmetics.